Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Spontaneous Urticaria · Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs — 145 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Novartis India projects

145 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 145 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

145 programs

Clinical programs

Page 1 of 4

  1. ACZ885

    Novartis Pharmaceuticals

    Muckle Wells Syndrome

    phase 3 small molecule completed

    1 trial

  2. AIN457

    Novartis Pharmaceuticals

    Non-infectious Uveitis

    phase 3 mab terminated

    1 trial

  3. AIN457 150 mg

    Novartis Pharmaceuticals

    Moderate to Severe Chronic Plaque-Type Psoriasis

    phase 3 small molecule completed

    1 trial

  4. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

  5. Aliskiren

    Novartis Pharmaceuticals

    Acute Decompensated Heart Failure

    phase 3 small molecule completed

    1 trial

  6. Asciminib

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  7. Bion 1301/FUB523

    Novartis Pharmaceuticals

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  8. CAAA601A62301

    Novartis Pharmaceuticals

    Gastroenteropancreatic neuroendocrine tumor (GEP-NET)

    phase 3 small molecule active

    1 trial

  9. CAAA617B12302

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  10. CAAA617C12301

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  11. CAAA617D12302

    Novartis Pharmaceuticals

    Oligometastatic prostate cancer (OMPC)

    phase 3 small molecule active

    1 trial

  12. CABL001A2001B

    Novartis Pharmaceuticals

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  13. CABL001J12301

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  14. CABL001J12302

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  15. CAIN457H1301

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  16. CAIN457M2301E1

    Novartis Pharmaceuticals

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  17. CAIN457R12301

    Novartis Pharmaceuticals

    Giant cell arteritis (GCA)

    phase 3 small molecule active

    1 trial

  18. CAIN457R1DE01

    Novartis Pharmaceuticals

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  19. CANAKINUMAB, PEMETREXED

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  20. CBAF312D2301

    Novartis Pharmaceuticals

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  21. CBYL719C2303

    Novartis Pharmaceuticals

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  22. CBYL719K12301

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  23. CBYL719P12201

    Novartis Pharmaceuticals

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  24. CCTL019A2205B

    Novartis Pharmaceuticals

    All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication

    phase 3 small molecule active

    1 trial

  25. CCTL019H2301

    Novartis Pharmaceuticals

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  26. CEXV811A12301

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  27. CFTY720D2311

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  28. CJDQ443B12301

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer harboring the KRAS G12C mutation

    phase 3 small molecule active

    1 trial

  29. CKJX839A12309

    Novartis Pharmaceuticals

    Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.

    phase 3 small molecule active

    1 trial

  30. CKJX839B12302

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  31. CKJX839C12303

    Novartis Pharmaceuticals

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  32. CKJX839C12304

    Novartis Pharmaceuticals

    homozygous familial hypercholesterolemia

    phase 3 small molecule active

    1 trial

  33. CKJX839D12303

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  34. CLEE011O12001

    Novartis Pharmaceuticals

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  35. CLEE011O12301C

    Novartis Pharmaceuticals

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  36. CLNP023A2301

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  37. CLNP023B12301

    Novartis Pharmaceuticals

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  38. CLNP023Q12301

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  39. CLOU064A2303B

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  40. CLOU064A2304

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  41. CLOU064C12301

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  42. CLOU064C12302

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  43. CLOU064C12306

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  44. CLOU064J12301

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  45. CLOU064J12302

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  46. CLOU064J12303B

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  47. CLOU064M12301

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  48. CLOU064O12301

    Novartis Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

145 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.